Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also issued reports on PYXS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Stifel Nicolaus cut their target price on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday. Royal Bank Of Canada decreased their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Tuesday. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pyxis Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Pyxis Oncology Stock Down 5.8%

Pyxis Oncology stock opened at $1.31 on Friday. The company’s 50-day moving average price is $1.49 and its 200-day moving average price is $2.49. The company has a market cap of $82.31 million, a PE ratio of -1.02 and a beta of 1.45. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings results on Monday, March 23rd. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter, compared to the consensus estimate of $0.13 million. As a group, sell-side analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Laurion Capital Management LP raised its holdings in shares of Pyxis Oncology by 32.3% in the 4th quarter. Laurion Capital Management LP now owns 4,796,479 shares of the company’s stock valued at $5,516,000 after purchasing an additional 1,170,505 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Pyxis Oncology by 0.7% during the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after purchasing an additional 14,566 shares in the last quarter. 683 Capital Management LLC increased its holdings in Pyxis Oncology by 69.9% during the fourth quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after buying an additional 366,910 shares during the period. Jane Street Group LLC increased its holdings in Pyxis Oncology by 158.8% during the fourth quarter. Jane Street Group LLC now owns 786,010 shares of the company’s stock valued at $904,000 after buying an additional 482,310 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Pyxis Oncology by 26.4% in the fourth quarter. Renaissance Technologies LLC now owns 728,380 shares of the company’s stock worth $838,000 after buying an additional 152,044 shares in the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Key Stories Impacting Pyxis Oncology

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and materially lifted multiple forward EPS forecasts (FY2026, FY2027, FY2028 and projected FY2030 profitability) and bumped several quarterly estimates — signaling improved multi‑year expectations and a $7 price target. These revisions are a bullish catalyst for upside longer term. HC Wainwright Lifts Earnings Estimates for Pyxis Oncology HC Wainwright Reaffirms Buy for Pyxis Oncology
• Neutral Sentiment: Market data shows an apparent zero reported short interest for March (likely a reporting artifact); this provides no reliable directional signal for near‑term price pressure.
• Negative Sentiment: Insider selling: Director Rachel Humphrey disclosed sales (most recently 13,896 shares at about $1.03). Insider exits can be viewed negatively by investors even if done for personal/liquidity reasons. Insider Selling Disclosure
• Negative Sentiment: Some sell‑side shops trimmed upside: Stifel lowered its price target (reducing implied upside), a sign that not all analysts are uniformly bullish. That can temper buying interest. Stifel Lowers Expectations for Pyxis Oncology
• Negative Sentiment: Within HC Wainwright’s note there was a downward revision to Q2‑2026 EPS (to -$0.36 from -$0.32), introducing mixed near‑term guidance despite the more positive multi‑year outlook — likely contributing to short‑term selling pressure.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.